Grover GJ[au] - Search Results

Year	Number of Results
1981	1
1982	1
1983	1
1984	4
1985	4
1986	4
1987	7
1988	8
1989	8
1990	12
1991	7
1992	9
1993	10
1994	12
1995	14
1996	11
1997	8
1998	3
1999	1
2000	3
2001	2
2002	4
2003	8
2004	6
2005	3
2006	6
2007	7
2008	3
2009	2
2010	1
2011	4
2012	2
2013	1
2014	1
2022	0

1

The IF(1) inhibitor protein of the mitochondrial F(1)F(0)-ATPase.

Green DW, Grover GJ. Green DW, et al. Among authors: grover gj. Biochim Biophys Acta. 2000 May 31;1458(2-3):343-55. doi: 10.1016/s0005-2728(00)00085-2. Biochim Biophys Acta. 2000. PMID: 10838049 Free article. Review.

2

Ifetroban sodium: an effective TxA2/PGH2 receptor antagonist.

Rosenfeld L, Grover GJ, Stier CT Jr. Rosenfeld L, et al. Among authors: grover gj. Cardiovasc Drug Rev. 2001 Summer;19(2):97-115. doi: 10.1111/j.1527-3466.2001.tb00058.x. Cardiovasc Drug Rev. 2001. PMID: 11484065 Review.

3

Recent advances in the development of agonists selective for beta1-type thyroid hormone receptor.

Malm J, Grover GJ, Färnegårdh M. Malm J, et al. Among authors: grover gj. Mini Rev Med Chem. 2007 Jan;7(1):79-86. doi: 10.2174/138955707779317885. Mini Rev Med Chem. 2007. PMID: 17266640 Review.

4

Thyroid hormone antagonists: potential medical applications and structure activity relationships.

Malm J, Färnegârdh M, Grover GJ, Ladenson PW. Malm J, et al. Among authors: grover gj. Curr Med Chem. 2009;16(25):3258-66. doi: 10.2174/092986709788803277. Epub 2009 Sep 1. Curr Med Chem. 2009. PMID: 19548868 Review.

5

ATP-Sensitive potassium channels: a review of their cardioprotective pharmacology.

Grover GJ, Garlid KD. Grover GJ, et al. J Mol Cell Cardiol. 2000 Apr;32(4):677-95. doi: 10.1006/jmcc.2000.1111. J Mol Cell Cardiol. 2000. PMID: 10756123 Review.

6

Energetic signalling in the control of mitochondrial F1F0 ATP synthase activity in health and disease.

Grover GJ, Marone PA, Koetzner L, Seto-Young D. Grover GJ, et al. Int J Biochem Cell Biol. 2008;40(12):2698-701. doi: 10.1016/j.biocel.2008.06.013. Epub 2008 Jul 30. Int J Biochem Cell Biol. 2008. PMID: 18707016 Review.

7

Pharmacological profile of the selective mitochondrial F1F0 ATP hydrolase inhibitor BMS-199264 in myocardial ischemia.

Grover GJ, Malm J. Grover GJ, et al. Cardiovasc Ther. 2008 Winter;26(4):287-96. doi: 10.1111/j.1755-5922.2008.00065.x. Cardiovasc Ther. 2008. PMID: 19035880 Free article. Review.

8

Therapeutic potential for thyroid hormone receptor-beta selective agonists for treating obesity, hyperlipidemia and diabetes.

Grover GJ, Mellström K, Malm J. Grover GJ, et al. Curr Vasc Pharmacol. 2007 Apr;5(2):141-54. doi: 10.2174/157016107780368271. Curr Vasc Pharmacol. 2007. PMID: 17430219 Review.

9

Protective effects of ATP sensitive potassium channel openers in models of myocardial ischaemia.

Grover GJ. Grover GJ. Cardiovasc Res. 1994 Jun;28(6):778-82. doi: 10.1093/cvr/28.6.778. Cardiovasc Res. 1994. PMID: 7923279 Review. No abstract available.

10

The role of ATP-sensitive potassium channels in myocardial ischemia: pharmacology and implications for the future.

Grover GJ. Grover GJ. EXS. 1996;76:313-24. doi: 10.1007/978-3-0348-8988-9_19. EXS. 1996. PMID: 8805803 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results